Drug Maker Shire Expands to Europe

The maker of Vyvanse has a new presence in European markets.

Pharmaceutical company Shire, maker of Vyvanse, has acquired rights to Equasym, a European medication used for the treatment of attention deficit hyperactivity disorder (ADD ADHD). Shire will continue to market Equasym within Europe, but it is not currently approved within the U.S. and Canada. Shire is also testing Vyvanse (now in Phase 3 trials) for approval in Europe.

Says Michael Cola, president of Shire’s Specialty Pharmaceuticals business: “Our expertise and portfolio of ADHD products will provide a strong foundation from which we can offer innovative treatments for adults and children with ADHD.”

Read more from Shire.